ROSGQ (Rosetta Genomics) Total Liabilities: $5.11 Mil (As of Jun. 2017)


What is Rosetta Genomics Total Liabilities?

Rosetta Genomics ROSGQ -99.00% Total Liabilities is $5.11 Mil as of Jun. 2017.

Rosetta Genomics's Total Liabilities for the quarter that ended in Jun. 2017 was $5.11 Mil.

Rosetta Genomics's quarterly Total Liabilities increased from Jun. 2016 ($3.15 Mil) to Dec. 2016 ($7.54 Mil) but then declined from Dec. 2016 ($7.54 Mil) to Jun. 2017 ($5.11 Mil).

Rosetta Genomics's annual Total Liabilities increased from Dec. 2014 ($2.21 Mil) to Dec. 2015 ($2.80 Mil) and increased from Dec. 2015 ($2.80 Mil) to Dec. 2016 ($7.54 Mil).

Rosetta Genomics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Rosetta Genomics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics Total Liabilities Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.63 2.25 2.21 2.80 7.54

Rosetta Genomics Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.49 2.80 3.15 7.54 5.11

Rosetta Genomics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Rosetta Genomics's Total Liabilities for the fiscal year that ended in Dec. 2016 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.804+(3.74+-4.4408920985006E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=7.54

Total Liabilities=Total Assets (A: Dec. 2016 )-Total Equity (A: Dec. 2016 )
=11.961-4.417
=7.54

Rosetta Genomics's Total Liabilities for the quarter that ended in Jun. 2017 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.714+(2.394+-4.4408920985006E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=5.11

Total Liabilities=Total Assets (Q: Jun. 2017 )-Total Equity (Q: Jun. 2017 )
=6.207-1.099
=5.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $5.11 Mil mean?
Rosetta Genomics (ROSGQ) has a Total Liabilities of $5.11 Mil as of Jun. 2017. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Rosetta Genomics and its competitors.
Is Rosetta Genomics' Total Liabilities too high?
Rosetta Genomics' current Total Liabilities is $5.11 Mil.
How does Rosetta Genomics' Total Liabilities compare to TEAR and IDTA?
Rosetta Genomics' Total Liabilities of $5.11 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Diagnostics & Research company?
A good Total Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Rosetta Genomics and its competitors. Rosetta Genomics's current Total Liabilities is $5.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Total Liabilities of $5.11 Mil. The current Total Liabilities is $5.11 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Total Liabilities is $5.11 Mil as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.